 SVB Leerink raised the price target on Nurix Therapeutics Inc NASDAQ: NRIX to 64 from 50, with an Outperform rating, seeing an upside of almost 92. Analyst Christopher Liu notes that Nurix presented preliminary NX-2127 pharmacokineticspharmacodynamics data. 